168 related articles for article (PubMed ID: 12804135)
1. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.
Rosenberg SA; Yang JC; Sherry RM; Hwu P; Topalian SL; Schwartzentruber DJ; Restifo NP; Haworth LR; Seipp CA; Freezer LJ; Morton KE; Mavroukakis SA; White DE
Hum Gene Ther; 2003 May; 14(8):709-14. PubMed ID: 12804135
[TBL] [Abstract][Full Text] [Related]
2. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.
Rosenberg SA; Zhai Y; Yang JC; Schwartzentruber DJ; Hwu P; Marincola FM; Topalian SL; Restifo NP; Seipp CA; Einhorn JH; Roberts B; White DE
J Natl Cancer Inst; 1998 Dec; 90(24):1894-900. PubMed ID: 9862627
[TBL] [Abstract][Full Text] [Related]
3. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
4. Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine.
Zhou WZ; Kaneda Y; Huang S; Morishita R; Hoon D
Gene Ther; 1999 Oct; 6(10):1768-73. PubMed ID: 10516727
[TBL] [Abstract][Full Text] [Related]
5. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen.
Gold JS; Ferrone CR; Guevara-Patiño JA; Hawkins WG; Dyall R; Engelhorn ME; Wolchok JD; Lewis JJ; Houghton AN
J Immunol; 2003 May; 170(10):5188-94. PubMed ID: 12734366
[TBL] [Abstract][Full Text] [Related]
6. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
7. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18.
Yamanaka R; Xanthopoulos KG
DNA Cell Biol; 2005 May; 24(5):317-24. PubMed ID: 15869409
[TBL] [Abstract][Full Text] [Related]
8. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.
Rosenberg SA; Yang JC; Schwartzentruber DJ; Hwu P; Topalian SL; Sherry RM; Restifo NP; Wunderlich JR; Seipp CA; Rogers-Freezer L; Morton KE; Mavroukakis SA; Gritz L; Panicali DL; White DE
Clin Cancer Res; 2003 Aug; 9(8):2973-80. PubMed ID: 12912944
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model.
Nawrath M; Pavlovic J; Moelling K
J Mol Med (Berl); 2001 Apr; 79(2-3):133-42. PubMed ID: 11357937
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse.
Triozzi PL; Aldrich W; Allen KO; Carlisle RR; LoBuglio AF; Conry RM
J Immunother; 2005; 28(4):382-8. PubMed ID: 16000957
[TBL] [Abstract][Full Text] [Related]
11. Reduced melanoma tumor formation in mice immunized with DNA expressing the melanoma-specific antigen gp100/pmel17.
Nawrath M; Pavlovic J; Dummet R; Schultz J; Strack B; Heinrich J; Moelling K
Leukemia; 1999 Apr; 13 Suppl 1():S48-51. PubMed ID: 10232365
[TBL] [Abstract][Full Text] [Related]
12. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100.
Spaner DE; Astsaturov I; Vogel T; Petrella T; Elias I; Burdett-Radoux S; Verma S; Iscoe N; Hamilton P; Berinstein NL
Cancer; 2006 Feb; 106(4):890-9. PubMed ID: 16404742
[TBL] [Abstract][Full Text] [Related]
13. Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo.
Wagner SN; Wagner C; Lührs P; Weimann TK; Kutil R; Goos M; Stingl G; Schneeberger A
J Invest Dermatol; 2000 Dec; 115(6):1082-7. PubMed ID: 11121145
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.
Yuan J; Ku GY; Gallardo HF; Orlandi F; Manukian G; Rasalan TS; Xu Y; Li H; Vyas S; Mu Z; Chapman PB; Krown SE; Panageas K; Terzulli SL; Old LJ; Houghton AN; Wolchok JD
Cancer Immun; 2009 Jun; 9():5. PubMed ID: 19496531
[TBL] [Abstract][Full Text] [Related]
15. Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.
Ginsberg BA; Gallardo HF; Rasalan TS; Adamow M; Mu Z; Tandon S; Bewkes BB; Roman RA; Chapman PB; Schwartz GK; Carvajal RD; Panageas KS; Terzulli SL; Houghton AN; Yuan JD; Wolchok JD
Clin Cancer Res; 2010 Aug; 16(15):4057-65. PubMed ID: 20647477
[TBL] [Abstract][Full Text] [Related]
16. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
[TBL] [Abstract][Full Text] [Related]
17. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
18. Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines.
Astsaturov I; Petrella T; Bagriacik EU; de Benedette M; Uger R; Lumber G; Berinstein N; Elias I; Iscoe N; Hammond C; Hamilton P; Spaner DE
Clin Cancer Res; 2003 Oct; 9(12):4347-55. PubMed ID: 14555505
[TBL] [Abstract][Full Text] [Related]
19. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
[TBL] [Abstract][Full Text] [Related]
20. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
